S 914 ISCommentsClose CommentsPermalink

To establish an independent Cures Acceleration Network agency, to sponsor promising translational research to bridge the gap between laboratory discoveries and life-saving therapies, to reauthorize the National Institutes of Health, and for other purposes.CommentsClose CommentsPermalink

April 28, 2009CommentsClose CommentsPermalink

Mr. SPECTER introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsCommentsClose CommentsPermalink

To establish an independent Cures Acceleration Network agency, to sponsor promising translational research to bridge the gap between laboratory discoveries and life-saving therapies, to reauthorize the National Institutes of Health, and for other purposes.CommentsClose CommentsPermalink

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,CommentsClose CommentsPermalink

SECTION 1. SHORT TITLE.

This Act may be cited as the ‘Cures Acceleration Network and National Institutes of Health Reauthorization Act of 2009’.CommentsClose CommentsPermalink

SEC. 2. CURES ACCELERATION NETWORK.

(a) Definitions- In this section--CommentsClose CommentsPermalink





(1) the term ‘medical product’ means a drug, device, biological product, or product that is a combination of drugs, devices, and biological products;CommentsClose CommentsPermalink





(2) the terms ‘drug’ and ‘device’ have the meanings given such terms in section 201 of the Federal Food, Drug, and Cosmetic Act; andCommentsClose CommentsPermalink





(3) the term ‘biological product’ has the meaning given such term in section 351 of the Public Health Service Act.CommentsClose CommentsPermalink





(b) Establishment of the Cures Acceleration Network- There is established an independent agency to be known as the Cures Acceleration Network (referred to in this section as ‘CAN’), which shall--CommentsClose CommentsPermalink





(1) be under the direction of a CAN Review Board (referred to in this section as the ‘Board’), described in subsection (d); andCommentsClose CommentsPermalink





(2) award grants and contracts to eligible entities, as described in subsection (e), to accelerate the development of cures and treatments of diseases, including through the development of medical products and behavioral therapies.CommentsClose CommentsPermalink





(c) Functions- The functions of the CAN are to--CommentsClose CommentsPermalink





(1) identify and promote revolutionary advances in basic research, translating scientific discoveries from bench to bedside;CommentsClose CommentsPermalink





(2) award grants and contracts to eligible entities;CommentsClose CommentsPermalink





(3) provide the resources through grants and contracts necessary for independent investigators, research organizations, biotechnology companies, academic research institutions, and other entities to develop medical products for the treatment and cure of diseases and disorders;CommentsClose CommentsPermalink





(4) reduce the barriers between laboratory discoveries and clinical trials for new therapies;CommentsClose CommentsPermalink





(5) facilitate priority review in the Food and Drug Administration for the medical products funded by the CAN; andCommentsClose CommentsPermalink





(6) accept donations, bequests, and gifts to the CAN.CommentsClose CommentsPermalink





(d) CAN Board-CommentsClose CommentsPermalink





(1) ESTABLISHMENT- There is established a Cures Acceleration Network Review Board (referred to in this section as the ‘Board’), which shall direct the activities of the Cures Acceleration Network.CommentsClose CommentsPermalink





(2) MEMBERSHIP-CommentsClose CommentsPermalink





(A) IN GENERAL-CommentsClose CommentsPermalink





(i) APPOINTMENT- The Board shall be comprised of 24 members who are appointed by the President and who serve at the pleasure of the President.CommentsClose CommentsPermalink





(ii) CHAIRPERSON AND VICE CHAIRPERSON- The President, by and with the advice and consent of the Senate, shall designate, from among the 24 members appointed under clause (i), one Chairperson of the Board (referred to in this section as the ‘Chairperson’) and one Vice Chairperson.CommentsClose CommentsPermalink





(B) TERMS-CommentsClose CommentsPermalink





(i) IN GENERAL- Each member shall be appointed to serve a 4-year term, except that any member appointed to fill a vacancy occurring prior to the expiration of the term for which the member’s predecessor was appointed shall be appointed for the remainder of such term.CommentsClose CommentsPermalink





(ii) CONSECUTIVE APPOINTMENTS; MAXIMUM TERMS- A member may be appointed to serve not more than 3 terms on the Board, and may not serve more than 2 such terms consecutively.CommentsClose CommentsPermalink





(C) QUALIFICATIONS-CommentsClose CommentsPermalink





(i) IN GENERAL- The President shall appoint individuals to the Board based solely upon the individual’s established record of distinguished service in one of the areas of expertise described in clause (ii). Each individual appointed to the Board shall be of distinguished achievement and have a broad range of disciplinary interests.CommentsClose CommentsPermalink





(ii) EXPERTISE- The President shall select individuals based upon the following requirements:CommentsClose CommentsPermalink





(I) For each of the fields of--CommentsClose CommentsPermalink

(aa) basic research;CommentsClose CommentsPermalink

(bb) medicine;CommentsClose CommentsPermalink

(cc) biopharmaceuticals;CommentsClose CommentsPermalink

(dd) discovery and delivery of medical products;CommentsClose CommentsPermalink

(ee) bioinformatics and gene therapy;CommentsClose CommentsPermalink

(ff) medical instrumentation; andCommentsClose CommentsPermalink

(gg) regulatory review and approval of medical products,CommentsClose CommentsPermalink

the President shall select at least 1 individual who is eminent in such fields.CommentsClose CommentsPermalink





(II) At least 4 individuals shall be recognized leaders in professional venture capital or private equity organizations and have demonstrated experience in private equity investing.CommentsClose CommentsPermalink





(III) At least 8 individuals shall represent disease advocacy organizations.CommentsClose CommentsPermalink





(3) EX-OFFICIO MEMBERS-CommentsClose CommentsPermalink





(A) APPOINTMENT- In addition to the 24 Board members described in paragraph (2), the President shall appoint as ex-officio members of the Board--CommentsClose CommentsPermalink





(i) a representative of the National Institutes of Health, recommended by the Secretary of the Department of Health and Human Services;CommentsClose CommentsPermalink





(ii) a representative of the Office of the Assistant Secretary of Defense for Health Affairs, recommended by the Secretary of Defense;CommentsClose CommentsPermalink





(iii) a representative of the Office of the Under Secretary for Health for the Veterans Health Administration, recommended by the Secretary of Veterans Affairs;CommentsClose CommentsPermalink





(iv) a representative of the National Science Foundation, recommended by the Chair of the National Science Board; andCommentsClose CommentsPermalink





(v) a representative of the Food and Drug Administration, recommended by the Commissioner of Food and Drugs.CommentsClose CommentsPermalink





(B) TERMS- Each ex-officio member shall serve a 3-year term on the Board, except that the Chairperson may adjust the terms of the initial ex-officio members in order to provide for a staggered term of appointment for all such members.CommentsClose CommentsPermalink





(4) RESPONSIBILITIES OF THE BOARD- The Board shall--CommentsClose CommentsPermalink





(A) advise the Chairperson with respect to policies, programs, and procedures for carrying out the Chairperson’s duties; andCommentsClose CommentsPermalink





(B) review applications for grants and contracts under subsection (e) and make recommendations to the Chairperson.CommentsClose CommentsPermalink





(5) AUTHORITY OF THE CHAIRPERSON- The Chairperson may--CommentsClose CommentsPermalink





(A) prescribe regulations regarding the manner in which the Chairperson’s duties shall be carried out, as the Chairperson determines necessary;CommentsClose CommentsPermalink





(B) appoint employees, subject to civil service laws, as necessary to carry out the Chairperson’s functions;CommentsClose CommentsPermalink





(C) define the duties, and supervise and direct the activities, of any employees appointed under subparagraph (B);CommentsClose CommentsPermalink





(D) use experts and consultants, including a panel of experts who may be employed as authorized by section 3109 of title 5, United States Code;CommentsClose CommentsPermalink





(E) accept and utilize the services of voluntary and uncompensated personnel and reimburse such personnel for travel expenses, as described in paragraph (7)(B);CommentsClose CommentsPermalink





(F) make advance, progress, or other payments without regard to section 3324 of title 31, United States Code;CommentsClose CommentsPermalink





(G) rent office space in the District of Columbia for use by the CAN;CommentsClose CommentsPermalink





(H) enter into agreements with other Federal agencies to carry out oversight of the grant program under subsection (e), which agreements may include provisions for financial reimbursement for the oversight provided by such agencies; andCommentsClose CommentsPermalink





(I) make other necessary expenditures.CommentsClose CommentsPermalink





(6) MEETINGS-CommentsClose CommentsPermalink





(A) IN GENERAL- The Board shall meet 4 times per calendar year, at the call of the Chairperson.CommentsClose CommentsPermalink





(B) QUORUM; REQUIREMENTS; LIMITATIONS-CommentsClose CommentsPermalink





(i) QUORUM- A quorum shall consist of a total of 13 members of the Board, excluding ex-officio members, with diverse representation as described in clause (iv).CommentsClose CommentsPermalink





(ii) CHAIRPERSON OR VICE CHAIRPERSON- Each meeting of the Board shall be attended by either the Chairperson or the Vice Chairperson.CommentsClose CommentsPermalink





(iii) LIMITATION- No member or ex-officio member of the Board may attend more than 2 meetings of the Board each calendar year with the exceptions of the Chairperson and Vice Chairperson, who may attend all such meetings.CommentsClose CommentsPermalink





(iv) DIVERSE REPRESENTATION- At each meeting of the Board, there shall be not less than one scientist, one representative of a disease advocacy organization, and one representative of a professional venture capital or private equity organization.CommentsClose CommentsPermalink





(7) COMPENSATION AND TRAVEL EXPENSES-CommentsClose CommentsPermalink





(A) COMPENSATION- Members shall receive compensation at a rate to be fixed by the Chairperson but not to exceed a rate equal to the daily equivalent of the annual rate of basic pay prescribed for level IV of the Executive Schedule under section 5315 of title 5, United States Code, for each day (including travel time) during which the member is engaged in the performance of the duties of the Board. All members of the Board who are officers or employees of the Untied States shall serve without compensation in addition to that received for their services as officers or employees of the United States.CommentsClose CommentsPermalink





(B) TRAVEL EXPENSES- Members of the Board shall be allowed travel expenses, including per diem in lieu of subsistence, at rates authorized for persons employed intermittently by the Federal Government under section 5703(b) of title 5, United States Code, while away from their homes or regular places of business in the performance of services for the Board.CommentsClose CommentsPermalink





(e) Grant Program-CommentsClose CommentsPermalink





(1) GRANTS AND CONTRACTS- The Chairperson shall, through the Board of the CAN, award grants and contracts to eligible entities to assist such entities in carrying out projects described in paragraph (3).CommentsClose CommentsPermalink





(2) AWARD PROCESS- The Chairperson of the Board may award a grant or contract under this subsection to an eligible entity only upon the approval of a majority of a quorum of the Board.CommentsClose CommentsPermalink





(3) USE OF FUNDS- Funds awarded under this subsection shall be used--CommentsClose CommentsPermalink





(A) to accelerate the development of cures and treatments, including through the development of medical products, behavioral therapies, and biomarkers that demonstrate the safety or effectiveness of medical products; orCommentsClose CommentsPermalink





(B) to help the award recipient establish protocols that comply with Food and Drug Administration standards and otherwise permit the recipient to meet regulatory requirements at all stages of development, manufacturing, review, approval, and safety surveillance of a medical product.CommentsClose CommentsPermalink





(4) ELIGIBLE ENTITIES- To receive a grant or contract under this subsection, an entity shall--CommentsClose CommentsPermalink





(A) be--CommentsClose CommentsPermalink





(i) an individual;CommentsClose CommentsPermalink





(ii) a group of individuals; orCommentsClose CommentsPermalink





(iii) a public or private entity, which may include a private or public research institution, an institution of higher education, a medical center, a biotechnology company, a pharmaceutical company, a disease advocacy organization, a patient advocacy organization, or an academic research institution;CommentsClose CommentsPermalink





(B) submit an application containing--CommentsClose CommentsPermalink





(i) a detailed description of the project for which the entity seeks such grant or contract;CommentsClose CommentsPermalink





(ii) a timetable for such project;CommentsClose CommentsPermalink





(iii) an assurance that the entity will submit--CommentsClose CommentsPermalink





(I) interim reports describing the entity’s--CommentsClose CommentsPermalink

(aa) progress in carrying out the project; andCommentsClose CommentsPermalink

(bb) compliance with all provisions of this section and conditions of receipt of such grant or contract; andCommentsClose CommentsPermalink

(II) a final report at the conclusion of the grant period, describing the outcomes of the project; andCommentsClose CommentsPermalink





(iv) a description of the protocols the entity will follow to comply with Food and Drug Administration standards and regulatory requirements at all stages of development, manufacturing, review, approval, and safety surveillance of a medical product; andCommentsClose CommentsPermalink





(C) provide such additional information as the Chairperson may require.CommentsClose CommentsPermalink





(5) STUDY SECTIONS OF THE CENTER FOR SCIENTIFIC REVIEW-CommentsClose CommentsPermalink





(A) IN GENERAL- The Chairperson may enter into an interagency agreement with the Center for Scientific Review within the National Institutes of Health to use the study sections of such Center to review applications submitted under paragraphs (4)(B) and additional information submitted under (4)(C) and to make recommendations to the Board. The Chairperson shall promulgate regulations and procedures to--CommentsClose CommentsPermalink





(i) ensure that each study section reviewing applications is composed of diverse members, as described in subparagraph (B);CommentsClose CommentsPermalink





(ii) require such study sections to create written records summarizing--CommentsClose CommentsPermalink





(I) all meetings and discussions of the study section; andCommentsClose CommentsPermalink





(II) the recommendations made by such study section to the Board; andCommentsClose CommentsPermalink





(iii) make the records described in clause (ii) available to the public in a manner that protects the privacy of applicants and panel members and any proprietary information from applicants.CommentsClose CommentsPermalink





(B) MEMBERSHIP- The Chairperson shall ensure that the study sections of the Center for Scientific Review that review applications submitted under this subsection are selected solely on the basis of established records of distinguished service and include--CommentsClose CommentsPermalink





(i) for each of the fields of--CommentsClose CommentsPermalink





(I) basic research;CommentsClose CommentsPermalink





(II) medicine;CommentsClose CommentsPermalink





(III) biopharmaceuticals;CommentsClose CommentsPermalink





(IV) discovery and delivery of medical products;CommentsClose CommentsPermalink





(V) bioinformatics and gene therapy; andCommentsClose CommentsPermalink





(VI) medical instrumentation,CommentsClose CommentsPermalink





at least 2 individuals with expertise in such fields;CommentsClose CommentsPermalink





(ii) at least 3 representatives of professional venture capital or private equity organizations with demonstrated experience in private equity investing; andCommentsClose CommentsPermalink





(iii) at least 3 representatives of disease advocacy organizations.CommentsClose CommentsPermalink





(C) FINANCIAL COMPENSATION- Any agreement under subparagraph (A) shall include an arrangement whereby the Chairperson reimburses the Center for Scientific Review for the services provided under such subparagraph.CommentsClose CommentsPermalink





(6) AWARDS-CommentsClose CommentsPermalink





(A) THE CURES ACCELERATION PARTNERSHIP AWARDS-CommentsClose CommentsPermalink





(i) INITIAL AWARD AMOUNT- Each award under this subparagraph shall be not more than $15,000,000 per project for the first fiscal year for which the project is funded, which shall be payable in one payment, except that the Chairperson of the Board may increase the award amount for an eligible entity if the Board so determines by a majority vote.CommentsClose CommentsPermalink





(ii) FUNDING IN SUBSEQUENT FISCAL YEARS- An eligible entity receiving an award under clause (i) may apply for additional funding for such project by submitting to the Board the information required under subparagraphs (B) and (C) of paragraph (4). The Chairperson may fund a project of such eligible entity in an amount not to exceed $15,000,000 for a fiscal year subsequent to the initial award under clause (i) if the Board so determines by majority vote.CommentsClose CommentsPermalink





(iii) MATCHING FUNDS- As a condition for receiving a grant or contract under this subparagraph, an eligible entity shall contribute to the project non-Federal funds in the amount of $1 for every $3 awarded under clauses (i) and (ii), except that the Chairperson may waive or modify such matching requirement by a majority vote of the Board.CommentsClose CommentsPermalink





(B) THE CURES ACCELERATION GRANT AWARDS-CommentsClose CommentsPermalink





(i) INITIAL AWARD AMOUNT- Each award under this subparagraph shall be not more than $15,000,000 per project for the first fiscal year for which the project is funded, which shall be payable in one payment, except that the Chairperson of the Board may increase the award amount for an eligible entity if the Board so determines by a majority vote.CommentsClose CommentsPermalink





(ii) FUNDING IN SUBSEQUENT FISCAL YEARS- An eligible entity receiving an award under clause (i) may apply for additional funding for such project by submitting to the Board the information required under subparagraphs (B) and (C) of paragraph (4). The Chairperson may fund a project of such eligible entity in an amount not to exceed $15,000,000 for a fiscal year subsequent to the initial award under clause (i) if the Board so determines by majority vote.CommentsClose CommentsPermalink





(7) SUSPENSION OF AWARDS FOR DEFAULTS, NONCOMPLIANCE WITH PROVISIONS AND PLANS, AND DIVERSION OF FUNDS; REPAYMENT OF FUNDS- The Chairperson may suspend the award to any entity upon noncompliance by such entity with provisions and plans under this section or diversion of funds.CommentsClose CommentsPermalink





(8) AUDITS- The Chairperson may enter into agreements with other entities to conduct periodic audits of the projects funded by grants or contracts awarded under this subsection.CommentsClose CommentsPermalink





(9) CLOSEOUT PROCEDURES- At the end of a grant or contract period, a recipient shall follow the closeout procedures under section 74.71 of title 45, Code of Federal Regulations (or any successor regulation).CommentsClose CommentsPermalink





(f) Staff- The CAN may employ such officers and employees (including experts and consultants), appointed by the Chairperson, as may be necessary to enable the CAN to carry out its functions under this section, and may employ and fix the compensation of such officers and employees.CommentsClose CommentsPermalink





(g) Gifts, Bequests, and Devises-CommentsClose CommentsPermalink





(1) IN GENERAL- The CAN may accept donations, bequests, and devises, with or without conditions, and transfers for tax purposes, for the purpose of aiding or facilitating the work of the CAN subject to the following:CommentsClose CommentsPermalink





(A) In any case in which money or other property is donated, bequeathed, or devised to the CAN without designation for the benefit of which such property is intended, and without condition or restriction other than that such property be used for the purposes of the CAN, such property shall be deemed to have been donated, bequeathed, or devised to the CAN and the Chairperson shall have authority to receive such property.CommentsClose CommentsPermalink





(B) In any case in which any money or other property is donated, bequeathed, or devised to the CAN with a condition or restriction, such property shall be deemed to have been donated, bequeathed, or devised to the CAN whose function it is to carry out the purpose or purposes described, or referred to, by the terms of such condition or restriction, and the Chairperson shall have authority to receive such property.CommentsClose CommentsPermalink





(C) For the purposes of subparagraph (B), if one or more of the purposes of such a condition or restriction is covered by the functions of the CAN, or if some of the purposes of such a condition or restriction are covered by the CAN, the Board shall determine an equitable manner for distribution by the CAN of the property so donated, bequeathed, or devised.CommentsClose CommentsPermalink





(D) For the purpose of Federal income tax, gift tax, and estate tax laws, any money or other property donated, bequeathed, or devised to the Chairperson pursuant to authority derived under this subsection shall be deemed to have been donated, bequeathed, or devised to, or for the use of, the United States.CommentsClose CommentsPermalink





(h) Conflicts of Interest-CommentsClose CommentsPermalink





(1) IN GENERAL- The Chairperson shall develop and enforce conflict of interest policies for the CAN and shall respond in a timely manner when such policies have been violated by a recipient of funds provided under a grant or contract awarded under this section.CommentsClose CommentsPermalink





(2) INFORMATION-CommentsClose CommentsPermalink





(A) IN GENERAL- In the case in which the principal investigator for a recipient described under subparagraph (B) has a conflict of interest, the Chairperson shall require the recipient to provide to the Chairperson the following information:CommentsClose CommentsPermalink





(i) The degree of the primary investigator’s financial interest, estimated to the nearest $1,000.CommentsClose CommentsPermalink





(ii) A detailed report explaining how the recipient will manage the primary investigator’s conflict of interest.CommentsClose CommentsPermalink





(B) RECIPIENT- A recipient described in this subparagraph is a recipient--CommentsClose CommentsPermalink





(i) of a grant or contract awarded under subsection (e); andCommentsClose CommentsPermalink





(ii) that receives more than $250,000 under such grant or contract.CommentsClose CommentsPermalink





(i) Authorization of Appropriations- For purposes of carrying out this section, there are authorized to be appropriated--CommentsClose CommentsPermalink





(1) for fiscal year 2010, $1,000,000,000 for awards described under subsection (e)(6)(A), including associated administrative costs;CommentsClose CommentsPermalink





(2) for fiscal year 2010, $1,000,000,000 for awards described under subsection (e)(6)(B), including associated administrative costs; andCommentsClose CommentsPermalink





(3) such sums as may be necessary for subsequent fiscal years.CommentsClose CommentsPermalink

SEC. 3. ORGANIZATION OF NATIONAL INSTITUTES OF HEALTH.

(a) Redesignation of Center on Minority Health and Health Disparities- Title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is amended--CommentsClose CommentsPermalink





(1) by redesignating subpart 6 of part E as subpart 20;CommentsClose CommentsPermalink





(2) by transferring subpart 20, as so redesignated, to part C of such title IV;CommentsClose CommentsPermalink





(3) by inserting subpart 20, as so redesignated, after subpart 19 of such part C; andCommentsClose CommentsPermalink





(4) in subpart 20, as so redesignated--CommentsClose CommentsPermalink





(A) by redesignating sections 485E through 485H as sections 464z-3 through 464z-6, respectively;CommentsClose CommentsPermalink





(B) by striking ‘National Center on Minority Health and Health Disparities’ each place such term appears and inserting ‘National Institute on Minority Health and Health Disparities’; andCommentsClose CommentsPermalink





(C) by striking ‘Center’ each place such term appears and inserting ‘Institute’.CommentsClose CommentsPermalink





(b) Purpose of Institute- Subsection (h) of section 464z-3 of the Public Health Service Act, as so redesignated, is amended--CommentsClose CommentsPermalink





(1) in paragraph (1), by striking ‘research endowments at centers of excellence under section 736.’ and inserting the following: ‘research endowments--CommentsClose CommentsPermalink





‘(1) at centers of excellence under section 736; andCommentsClose CommentsPermalink





‘(2) at centers of excellence under section 464z-4.’; andCommentsClose CommentsPermalink





(2) in paragraph (2)(A), by striking ‘average’ and inserting ‘median’.CommentsClose CommentsPermalink





(c) Technical Amendment- Section 401(b)(24) of the Public Health Service Act (42 U.S.C. 281(b)(24)) is amended by striking ‘Center’ and inserting ‘Institute’.CommentsClose CommentsPermalink





(d) Conforming Amendment- Subsection (d)(1) of section 903 of the Public Health Service Act (42 U.S.C. 299a-1(d)(1)) is amended by striking ‘section 485E’ and inserting ‘section 464z-3’.CommentsClose CommentsPermalink

SEC. 4. CONFLICTS OF INTEREST.

Section 402 of the Public Health Service Act (42 U.S.C. 282) is amended by adding at the end the following:CommentsClose CommentsPermalink





‘(m) Enforcement of Conflict of Interest Policies-CommentsClose CommentsPermalink





‘(1) IN GENERAL- The Director shall develop and enforce the conflict of interest policies for the National Institutes of Health and shall respond in a timely manner when such policies have been violated by a recipient of funds provided under a grant or contract awarded under this title.CommentsClose CommentsPermalink





‘(2) INFORMATION-CommentsClose CommentsPermalink





‘(A) IN GENERAL- In the case in which the principal investigator for a recipient described under subparagraph (B) has a conflict of interest, the Director shall require the recipient to provide to the Director the following information:CommentsClose CommentsPermalink





‘(i) The degree of the primary investigator’s financial interest, estimated to the nearest $1,000.CommentsClose CommentsPermalink





‘(ii) A detailed report explaining how the recipient will manage the primary investigator’s conflict of interest.CommentsClose CommentsPermalink





‘(B) RECIPIENT- A recipient described in this subparagraph is a recipient--CommentsClose CommentsPermalink





‘(i) of a grant or contract awarded under this title; andCommentsClose CommentsPermalink





‘(ii) that receives more than $250,000 under such grant or contract.’.CommentsClose CommentsPermalink

SEC. 5. AUTHORIZATION OF APPROPRIATIONS.

(a) Authorization of Appropriations- Section 402A of the Public Health Service Act (42 U.S.C. 282a) is amended by striking paragraphs (1) through (3) of subsection (a) and inserting the following:CommentsClose CommentsPermalink





‘(1) $40,000,000,000 for fiscal year 2010; andCommentsClose CommentsPermalink





‘(2) such sums as may be necessary for each of fiscal years 2011 and 2012.’.CommentsClose CommentsPermalink





(b) Office of the Director- Subparagraph (b) of section 402A of the Public Health Service Act (42 U.S.C. 282a(b)) is amended by striking ‘2007 through 2009’ and inserting ‘2010 through 2012’.CommentsClose CommentsPermalink